Medicenna Therapeutics Corp. MDNA.TO
Nov 4, 2026, 3:00 PM EST
- YTD
- -52.72%
- 1 year
- -70.81%
- Market cap
- 40.15M
- EPS (ttm)
- -0.22
- Shares out
- 78.16M
- Forward P/E
- -8.00
- YTD return
- -52.72%
- 1-year return
- -70.81%
- Volume
- 11.13K
- Avg volume
- 48.48K
- Open
- 0.445
- Previous close
- 0.415
- Day's range
- 0.42 – 0.445
- 52-week range
- 0.335 – 1.78
- Beta
- 1.19
- Price target
- 4.38 (+905.7%)
2Y -1.9350 (-81.65%)
Key statistics
- Enterprise value
- 75.73M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 24.53
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -30.38K
- Total cash
- 35.63M
- Total debt
- 0
- Return on equity
- -105.43%
- Short % of float
- 0.15%
- 50-day average
- 1.96
- 200-day average
- 2.03
Analyst view
- Target (low)
- 3.75
- Target (mean)
- 4.38
- Target (high)
- 5.00
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 18, 2020 | Oppenheimer | init | — | Outperform |
| Dec 17, 2020 | Oppenheimer | init | — | Outperform |
| Sep 10, 2020 | HC Wainwright & Co. | init | — | Buy |
About Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops bizaxofusp (MDNA55), an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a masked bi-functional anti-PD1-IL2 Superkine for various solid tumors; and MDNA132, an IL-13 Superkine for various tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, inhibitors, antibodies, cytokines, or other Superkines Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- medicenna.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on MDNA.TO — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Org Partners LLC | 0.16% | 125,000 | 230.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 34,144 | 62.82K | Oct 30, 2023 |